Back

Trial discontinued. This compound has not appeared in active U.S. clinical trials for some time and may have been withdrawn or abandoned. Existing favourites and notes are preserved for historical reference.

Mazdutide

PipelinePhase 2PeptideInvestigational

Sponsor:: Eli Lilly and Company
Active US trials:: 1
Earliest primary completion:: Mar 19, 2026

👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

Synopsis

Generated with AlphaAI

Product:

Mazdutide

Category:

Indication:

Mechanism:

Safety:

Dosing:

Patient:

Reviews:

No reviews yet

Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (1)

NCT	Phase	Status	Sponsor	Primary Completion
NCT06817356	Phase 2	ACTIVE_NOT_RECRUITING	Eli Lilly and Company	Mar 19, 2026

About this drug

Status

Discontinued — no longer in active trials

Last Refreshed

Jul 15, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Mazdutide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers